Flare on [18F]PSMA-1007 PET/CT after short-term androgen deprivation therapy and its correlation to FDG uptake: possible marker of tumor aggressiveness in treatment-naïve metastatic prostate cancer patients

dc.contributor.authorMalaspina Simona
dc.contributor.authorEttala Otto
dc.contributor.authorTolvanen Tuula
dc.contributor.authorRajander Johan
dc.contributor.authorEskola Olli
dc.contributor.authorBoström Peter J.
dc.contributor.authorKemppainen Jukka
dc.contributor.organizationfi=PET-keskus|en=Turku PET Centre|
dc.contributor.organizationfi=kirurgia|en=Surgery|
dc.contributor.organizationfi=kliininen fysiologia ja isotooppilääketiede|en=Clinical Physiology and Isotope Medicine|
dc.contributor.organizationfi=tyks, vsshp|en=tyks, varha|
dc.contributor.organization-code1.2.246.10.2458963.20.14646305228
dc.contributor.organization-code1.2.246.10.2458963.20.75985703497
dc.contributor.organization-code1.2.246.10.2458963.20.97295082107
dc.contributor.organization-code2607322
dc.contributor.organization-code2609810
dc.converis.publication-id176701276
dc.converis.urlhttps://research.utu.fi/converis/portal/Publication/176701276
dc.date.accessioned2022-11-29T15:48:33Z
dc.date.available2022-11-29T15:48:33Z
dc.description.abstract<p><b>Purpose </b>Short-term androgen deprivation therapy (ADT) is known to increase heterogeneously prostate-specific membrane antigen (PSMA) expression. This phenomenon might indicate the potential of cancer lesions to respond to ADT. In this prospective study, we evaluated the flare on [F-18]PSMA-1007 PET/CT after ADT in metastatic prostate cancer (PCa). Given that aggressive PCa tends to display FDG uptake, we particularly investigated whether the changes in PSMA uptake might correlate with glucose metabolism.<br></p><p><b>Methods </b>Twenty-five men with newly diagnosed treatment-naive metastatic PCa were enrolled in this prospective registered clinical trial. All the patients underwent [F-18]PSMA-1007 PET/CT immediately before and 3-4 weeks after ADT initiation (degarelix). Before ADT, [F-18]FDG PET/CT was also performed. Standardized uptake values (SUV)max of primary and metastatic lesions were calculated in all PET scans. Serum PSA and testosterone blood samples were collected before the two PSMA PET scans. The changes in PSMA uptake after ADT were represented as Delta SUVmax.<br></p><p><b>Results </b>All the patients reached castration levels of testosterone at the time of the second [F-18]PSMA-1007 PET/CT. Overall, 57 prostate, 314 lymph nodes (LN), and 406 bone lesions were analyzed. After ADT, 104 (26%) bone, 33 (11%) LN, and 6 (11%) prostate lesions showed an increase (>= 20%) in PSMA uptake, with a median Delta SUVmax of + 50%, + 60%, and + 45%, respectively. Among the lesions detected at the baseline [F-18]PSMA-1007 PET/CT, 63% bone and 46% LN were FDG-positive. In these metastases, a negative correlation was observed between the PSMA Delta SUVmax and FDG SUVmax (p < 0.0001). Moreover, a negative correlation between the Delta SUVmax and the decrease in serum PSA after ADT was noted (p < 0.0001).<br></p><p><b>Conclusions </b>A heterogeneous increase in PSMA uptake after ADT was detected, most evidently in bone metastases. We observed a negative correlation between the PSMA flare and the intensity of glucose uptake as well as the decrease of serum PSA, suggesting that lesions presenting with such flare might potentially be less aggressive.<br></p>
dc.identifier.eissn1619-7089
dc.identifier.jour-issn1619-7070
dc.identifier.olddbid190204
dc.identifier.oldhandle10024/173295
dc.identifier.urihttps://www.utupub.fi/handle/11111/33778
dc.identifier.urlhttps://doi.org/10.1007/s00259-022-05970-y
dc.identifier.urnURN:NBN:fi-fe2022110164039
dc.language.isoen
dc.okm.affiliatedauthorMalaspina, Simona
dc.okm.affiliatedauthorEttala, Otto
dc.okm.affiliatedauthorTolvanen, Tuula
dc.okm.affiliatedauthorEskola, Olli
dc.okm.affiliatedauthorBoström, Peter
dc.okm.affiliatedauthorKemppainen, Jukka
dc.okm.affiliatedauthorDataimport, tyks, vsshp
dc.okm.discipline3121 Internal medicineen_GB
dc.okm.discipline3122 Cancersen_GB
dc.okm.discipline3121 Sisätauditfi_FI
dc.okm.discipline3122 Syöpätauditfi_FI
dc.okm.internationalcopublicationnot an international co-publication
dc.okm.internationalityInternational publication
dc.okm.typeA1 ScientificArticle
dc.publisherSPRINGER
dc.publisher.countryGermanyen_GB
dc.publisher.countrySaksafi_FI
dc.publisher.country-codeDE
dc.relation.doi10.1007/s00259-022-05970-y
dc.relation.ispartofjournalEuropean Journal of Nuclear Medicine and Molecular Imaging
dc.source.identifierhttps://www.utupub.fi/handle/10024/173295
dc.titleFlare on [18F]PSMA-1007 PET/CT after short-term androgen deprivation therapy and its correlation to FDG uptake: possible marker of tumor aggressiveness in treatment-naïve metastatic prostate cancer patients
dc.year.issued2023

Tiedostot

Näytetään 1 - 1 / 1
Ladataan...
Name:
s00259-022-05970-y.pdf
Size:
1.1 MB
Format:
Adobe Portable Document Format